Jubilant Pharmova Ltd. News and Updates

Name: Latest research reports of Jubilant Pharmova Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Jubilant Pharmova Ltd.
Rating: 5
Author: ICICI Securities Limited

Keep track of all breaking news on Jubilant Pharmova Ltd. from all sources in a single place.

Load latest

Jubilant Pharmova Ltd.

04 Jan 2017

1084.80

-0.58%

Jubilant Life shares rally on US contract

Business Line

Shares of Jubilant Life Sciences today surged 12.5 per cent after the company said its subsidiary has signed long-term contracts in the US for the supply of some of its diagnostic and therapeutic...

Jubilant Pharmova Ltd. has gained 20.15% in the last 6 Months

Jubilant Life signs deals for diagnostic product supply

Business Line | 04 Jan 2017 1 more

Jubilant Pharmova Ltd.

20 Dec 2016

1084.80

-0.58%

Jubilant Life Sciences Announces Price Hike Of Up To 15%

NDTV Profit

Jubilant Life Sciences is engaged in pharmaceuticals, life science ingredients and drug discovery solutions.

Jubilant Pharmova Ltd. is trading above its 200 day SMA of 1037.5

Jubilant Life Sciences hikes prices by up to 15% on select products

Business Standard | 20 Dec 2016

Jubilant Pharmova Ltd.

25 Nov 2016

1084.80

-0.58%

Jubilant Life Seeks Shareholders' Nod To Raise Upto Rs 1,000 Crore

NDTV Profit

This approval to the board to raise the amount also stipulates that this could be done in one or more series/tranches during a period of one year from the date of passing the resolution, it added.

Jubilant Pharmova Ltd. has gained 20.15% in the last 6 Months

Company news

Business Line | 25 Nov 2016 1 more

Jubilant Pharmova Ltd.

01 Nov 2016

1084.80

-0.58%

ANDA approval may activate Jubilant Life

Business Line

Shares of Jubilant Life Sciences may remain active, as the company has received final approval for the generic version of Crestor tablets from the US Food and Drug Administration. It has received...

Number of FII/FPI investors increased from 196 to 233 in Jun 2025 qtr.

Jubilant Pharmova Ltd.

28 Oct 2016

1084.80

-0.58%

Jubilant Life Sciences

Buy: Jubilant Pharmova Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues de-grew 3% YoY to | 1419 crore (I-direct estimates: | 1434 crore). Revenues in the pharmaceutical business grew 8% YoY to | 807 crore (I-direct estimate: | 795 crore) while life science ingredients (LSI) revenues de-grew 14% YoY to | 613 crore (I-direct estimate: | 620 crore) due to a decline in life science chemicals segment led by lower crude prices and product calibration EBITDA margins increased 207 bps YoY to 24.0% (I-direct estimates:...

Jubilant Pharmova Ltd. is trading above its 200 day SMA of 1037.5

Jubilant Pharmova Ltd.

27 Oct 2016

1084.80

-0.58%

Jubilant Life Q2 net up 14.51% at Rs145 crore

livemint

Jubilant Life Sciences posted a net profit after taxes, minority interest and share of profit/loss of associates of Rs126.42 crore for the corresponding period of the previous fiscal

Number of FII/FPI investors increased from 196 to 233 in Jun 2025 qtr.

Jubilant Pharmova Ltd.

18 Oct 2016

1084.80

-0.58%

Today's Pick: Jubilant Life Sciences (English) by Lavanya Prabhakaran

Business Line

Jubilant Pharmova Ltd. is trading above its 200 day SMA of 1037.5

Jubilant Life Sciences (689.5)

Business Line | 18 Oct 2016 1 more

Jubilant Pharmova Ltd.

14 Oct 2016

1084.80

-0.58%

Jubilant Life raises Rs 50 cr by issue of commercial papers

Business Line

Drug firm Jubilant Life Sciences today said it has raised Rs 50 crore through issuing commercial papers. The company has issued commercial papers for an aggregate amount of Rs 50 crore on...

Number of FII/FPI investors increased from 196 to 233 in Jun 2025 qtr.

Jubilant Pharmova Ltd.

13 Oct 2016

1084.80

-0.58%

Jubilant Life gets USFDA nod for urinary incontinence drug

Business Line

Jubilant Life Sciences has received the final approval from the US health regulator for Darifenacin Extended-Release Tablets, used for the treatment of urinary incontinence. The company has...

Jubilant Pharmova Ltd. has gained 20.15% in the last 6 Months

Jubilant Life gets USFDA nod for urinary incontinence drug

Business Standard | 13 Oct 2016

Jubilant Pharmova Ltd.

05 Oct 2016

1084.80

-0.58%

Jubilant arm gets TGA nod for lung scan drug

Business Line

Jubilant Life Sciences today said its wholly-owned subsidiary has received approval from the Australian health regulator Therapeutic Goods Administration (TGA) for Lyophilised kit for the...

Number of FII/FPI investors increased from 196 to 233 in Jun 2025 qtr.

Is Jubilant Life Sciences Ltd. worth buying?

383 Votes:

Buy 80.42%

Sell 11.23%

Hold 8.36%

35.26% Gain from 52W Low

Jubilant Pharmova Ltd. News and Updates

Keep track of all breaking news on Jubilant Pharmova Ltd. from all sources in a single place.